Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.

Annals of hematology - 1 Oct 2008

Larsen T S, Bjerrum O W, Pallisgaard N, Andersen M T, Møller M B, Hasselbalch H C

Abstract excerpt

Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Bone Marrow Cells
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Janus Kinase 2

Share to Point Mutation

Share to Polycythemia Vera

Share to Recombinant Proteins

Source

Identifiers

PMID: 18481066
DOI: 10.1007/s00277-008-0498-4

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.PMID 18481066Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.Semantic proximity Read ↗

Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.Semantic proximity Read ↗

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia veraSemantic proximity Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].Semantic proximity Read ↗

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.Semantic proximity Read ↗

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.Semantic proximity Read ↗

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.